Drug Adherence in Hypertension and Cardiovascular Protection

  • Michel Burnier

Table of contents

  1. Front Matter
    Pages i-viii
  2. Michel Burnier, Bernard Vrijens
    Pages 1-8
  3. Measuring Drug Adherence

    1. Front Matter
      Pages 9-9
    2. Michel Burnier, Grégoire Wuerzner
      Pages 11-19
    3. Pankaj Gupta, Prashanth Patel, Maciej Tomaszewski
      Pages 29-41
    4. Ulla Hjørnholm, Mikaela Aamodt, Anne Cecilie Larstorp, Fadl Elmula M. Fadl Elmula, Aud Høieggen, Marit Helen Andersen et al.
      Pages 57-85
  4. Risk Factors for Non-adherence

    1. Front Matter
      Pages 105-105
    2. Valentina Forni Ogna, Michel Burnier
      Pages 107-122
  5. Adherence in Hypertension and CV Protection

    1. Front Matter
      Pages 143-143
    2. Michel Burnier
      Pages 145-151
    3. Ian M. Kronish, Nathalie Moise
      Pages 153-172
    4. Miriam Qvarnström, Björn Wettermark, Thomas Kahan
      Pages 173-184
    5. Idir Hamdidouche, Vincent Jullien, Stéphane Laurent, Michel Azizi
      Pages 185-197
    6. Maarit Jaana Korhonen, Emma Aarnio
      Pages 199-217
    7. Todd Ruppar
      Pages 219-223
    8. Massimo Volpe, Giuliano Tocci, Giovanna Gallo
      Pages 225-235
    9. Christopher E. Clark
      Pages 237-252
    10. Marie P. Schneider, Parisa Aslani
      Pages 253-269
    11. Parati Gianfranco, Pellegrini Dario, Torlasco Camilla
      Pages 283-293
  6. Health Care Consequences of Non-adherence

    1. Front Matter
      Pages 295-295
    2. Sylvie Perreault
      Pages 297-314

About this book


This book provides a critical and comprehensive review of the methodologies available for measuring drug adherence in clinical practice, including those relying on emerging technologies. The authors discuss the risk factors of non-adherence and shed light on how to identify patients at risk of poor adherence. Drug therapies in chronic diseases rely heavily on the patient's adherence, since drugs that are not taken are ineffective and leave the patient at high risk of developing clinical complications. Given the absence of new drugs for the treatment of hypertension, drug adherence is particularly important in these patients to improve blood pressure control. The book further investigates a new aspect, namely the importance of drug adherence in clinical trials and studies and draws attention to the limits of developing drugs without significant information on drug adherence. Several chapters are dedicated to the importance of adherence in specific forms of hypertension, such as resistant hypertension, dyslipidemia and hypertension associated with cardiovascular risk. As experts confronted with drug adherence in their daily practice, the authors analyse the real effectiveness of several interventions aimed at improving drug adherence and put particular emphasis on the importance of an interdisciplinary approach involving nurses and pharmacists. The volume also includes a careful analysis of the health and economic impact of poor adherence. The book is aimed at physicians, pharmacists, students and all health professionals dealing not only with hypertension or dyslipidemia, but also with chronic asymptomatic diseases such as diabetes, HIV or chronic respiratory diseases.


drug adherence monitoring resistant hypertension clinical trials healthcare network cost-effectiveness dyslipidemia pharmacotherapy cardiovascular prevention

Editors and affiliations

  • Michel Burnier
    • 1
  1. 1.Service of Nephrology and HypertensionCHUV, University of LausanneLausanneSwitzerland

Bibliographic information

  • DOI
  • Copyright Information Springer International Publishing AG, part of Springer Nature 2018
  • Publisher Name Springer, Cham
  • eBook Packages Medicine
  • Print ISBN 978-3-319-76592-1
  • Online ISBN 978-3-319-76593-8
  • Series Print ISSN 2366-4606
  • Series Online ISSN 2366-4614
  • Buy this book on publisher's site